Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05863754

Grasp-Release Assessment of a Networked Neuroprosthesis Device

The overall objective of this trial is to characterize the safety and effectiveness of the Networked Neuroprosthesis Device - Upper Extremity (NP-UE) in individuals living with cervical SCI.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MetroHealth Medical Center

Cleveland, Ohio, 44109, United States

Location status: Recruiting

Location contact

Anne Bryden, Ph.D, OTR/L

CONTACT

[email protected]

216-957-3594

About this study

The Networked Neuroprosthesis(NNP) is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals. The NNP-UE Configuration activates nerves of the upper extremity (arm and hand), and senses voluntary motion and/or electromyogram (EMG) in order to provide hand grasp.

The proposed work is focused on restoration of hand and reaching functions for people with cervical level spinal cord injury. For individuals who have sustained this injury, restoration of hand function is their top priority, and existing alternatives are limited. Neuroprosthesis are the most promising method for significant gain in hand and arm function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, age > 16 years.
  • Cervical level spinal cord injury, as defined by:
  • International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor level of C1 through C7 and
  • American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade A, B, or C;
  • Six months or more post-injury (neurostability);
  • Neurologically stable following any nerve transfers affecting the upper extremity (typically, one year post surgery);
  • Musculoskeletally and neurologically stable following any tendon transfers affecting the upper extremity (typically, 6-months).
  • Peripheral nerve innervation to upper extremity muscles, including a grade 3/5 or higher Stimulated Manual Muscle Test (SMMT) strength in at least two of the following muscles in one arm:
  • Adductor Pollicus, Abductor Pollicus Brevis (AbPB), Flexor Pollicus Longus (FPL), Extensor Pollicus Longus (EPL)/Extensor Pollicus Brevis (EPB), Extensor Digitorum Communis (EDC), Flexor Digitorum Superficialis (FDS), Flexor Digitorum Profundus (FDP), Pronator Quadratus (PQ), Extensor Carpi Ulnaris (ECU), Extensor Carpi Radialis Brevis (ECRB), Extensor Carpi Radialis Longus (ECRL), Flexor Carpi Ulnaris (FCU), Flexor Carpi Radialis (FCR), First Dorsal Interosseous(1DI), triceps,
  • At least two of the grade 3/5 or higher excitable muscles must also have grade 2/5 or lower voluntary strength;
  • Good proximal upper extremity strength as defined by biceps/brachialis/brachioradialis strength of 2/5 or higher on Manual Muscle Test on the side intended for implantation;
  • Medically stable;
  • Able to understand and provide informed consent.

Exclusion criteria

  • Other neurological conditions (MS(multiple Sclerosis), diabetes with peripheral nerve involvement); Associated peripheral nerve / brachial plexus injury
  • Progressive SCI;
  • Co-existing cervical spine pathology (syrinx, unstable segment)
  • Active implantable medical device (AIMD) such as a pacemaker or defibrillator;
  • Active untreated infection such as pressure injury, urinary tract infection, pneumonia;
  • History of coagulopathy, HIV, cardiopulmonary disease, bradycardia, poorly controlled autonomic dysreflexia, or chronic obstructive pulmonary disease that would preclude safe participation in the trial as determined by the investigator;
  • Unhealed fractures that prevent functional use of arm;
  • Extensive upper extremity denervation (fewer than two excitable hand muscles);
  • Involvement in other ongoing clinical studies that exclude concurrent involvement in this study;
  • Disorder or condition that requires MRI monitoring;
  • Mechanical ventilator dependency;
  • Currently pregnant (neuroprosthesis implantation delayed until no longer pregnant);
  • Presence of disease that might interfere with participant safety, compliance, or evaluation of the condition under study;
  • Other significant medical findings that, in the opinion of the investigator, preclude safe participation in the trial.

Treatment and study plan

Networked Neuroprosthesis Device

Device

The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.

Primary outcomes

  1. Change in Grasp-Release Test

    Time frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant

    Ability to pick up, move, and release six standard objects

Secondary outcomes

  1. Change in Grasp Dynameter(force)

    Time frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant

    Measure of muscular strength or the maximum force/tension generated by one's forearm muscles.

  2. Change in Canadian Occupational Performance Measure (COPM)

    Time frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant

    Evidence-based outcome measure designed to capture a client's self-perception of performance in everyday living, over time

  3. Change in Activities of Daily Living (ADL) Abilities Test

    Time frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant

    The Activities of Daily Living (ADL) profile uses both observation and interview to assess function in tasks completed in the personal, home, and community environments.

  4. Change in Spinal Cord Independence Measure III (SCIM-III)

    Time frame: Pre-implant and three months post-implant, 6 months post implant, 12 months post implant

    The measure address three specific areas of function in patients with spinal cord injuries (SCI). It looks at self-care (feeding, grooming, bathing, and dressing), respiration and sphincter management, and a patient's mobility abilities (bed and transfers and indoors/outdoors)

Study contacts

Contact information is provided by the study sponsor or research team.

Anne Bryden, Ph.D, OTR/L

CONTACT

[email protected]

216-957-3594

KIm Walsh, OTR/L

CONTACT

[email protected]

216-957-3512

Sponsors and collaborators

Lead sponsor

MetroHealth Medical Center

Other

Collaborators

  • Case Western Reserve University
  • National Institute of Neurological Disorders and Stroke (NINDS)

Registry information

Acronym: GRANND

Important dates

Study start
2022
Primary completion
2027
Study completion
2028
First posted
May 18, 2023
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.